Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018

Neurocrine Bio. (NBIX) PT Raised to $100 at Oppenheimer

February 14, 2018 6:21 AM EST

Oppenheimer raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $95.00) while maintaining a Outperform rating following Q4 results.

Analyst Jay Olson commented, "NBIX shares have outperformed YTD (+8% vs. NBI +1% and S&P 500 flat), largely driven by impressive 4Q17 sales of... More